[1] Al-Tawfiq JA, Zumla A, Gautret P, Gray GC, Hui DS, Al-Rabeeah AA, et al. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014;14:992–1000. https://doi.org/10.1016/S1473-3099(14)70840-0.
[2] Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology 2018;23:130–7. https://doi.org/10.1111/resp.13196.
[3] Khandaker G, Dierig A, Rashid H, King C, Heron L, Booy R. Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respi Viruses 2011;5:148–56. https://doi.org/10.1111/j.1750-2659.2011.00199.x.
[4] Short KR, Kedzierska K, van de Sandt CE. Back to the Future: Lessons Learned From the 1918 Influenza Pandemic. Front Cell Infect Microbiol 2018;8:343. https://doi.org/10.3389/fcimb.2018.00343.
[5] Martín-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community-acquired respiratory coinfection in critically III patients with pandemic 2009 influenza A(H1N1) virus. Chest 2011;139:555–62. https://doi.org/10.1378/chest.10-1396.
[6] Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ. Severe acute respiratory syndrome in Taiwan: Analysis of epidemiological characteristics in 29 cases. J Infect 2004;48:23–31. https://doi.org/10.1016/j.jinf.2003.09.004.
[7] Arabi YM, Deeb AM, Al-Hameed F, Mandourah Y, Almekhlafi GA, Sindi AA, et al. Macrolides in critically ill patients with Middle East Respiratory Syndrome. Int J Infect Dis 2019;81:184–90. https://doi.org/10.1016/j.ijid.2019.01.041.
[8] Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 2020;10. https://doi.org/10.1016/j.cmi.2020.07.016.
[9] Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect 2020. https://doi.org/10.1016/j.jinf.2020.05.046.
[10] Contou D, Claudinon A, Pajot O, Micaëlo M, Longuet Flandre P, Dubert M, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU. Ann Intensive Care 2020;10. https://doi.org/10.1186/s13613-020-00736-x.
[11] Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis 2020;20. https://doi.org/10.1186/s12879-020-05374-z.
[12] Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa530.
[13] SFR. Compte-rendu TDM THORACIQUE 2020:1. https://ebulletin.radiologie.fr/actualités-covid-19/compte-rendu-tdm-thoracique-iv.
[14] Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2020;▪:1. https://doi.org/10.1016/j.cmi.2020.07.041.
[15] Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020;26:1395. https://doi.org/10.1016/j.cmi.2020.06.025.
[16] Townsend L, Hughes G, Kerr C, Kelly M, O’Connor R, Sweeney E, et al. Bacterial pneumonia coinfection and antimicrobial therapy duration in SARS-CoV-2 (COVID-19) infection. JAC-Antimicrobial Resist 2020;2. https://doi.org/10.1093/jacamr/dlaa071.
[17] Jung HS, Kang BJ, Ra SW, Seo KW, Jegal Y, Jun JB, et al. Elucidation of bacterial pneumonia-causing pathogens in patients with respiratory viral infection. Tuberc Respir Dis (Seoul) 2017;80:358–67. https://doi.org/10.4046/trd.2017.0044.
[18] Sobieszczańska BM, Kasprzykowska U, Duda-Madej A, Secewicz A, Marciniak J, Gósciniak G. Relevance of serology for Mycoplasma pneumoniae infection among children with persistent cough. Adv Clin Exp Med 2014;23:185–90. https://doi.org/10.17219/acem/37046.
[19] Zhang G, Hu C, Luo L, Chen Y, Li J, Peng Z, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol 2020. https://doi.org/10.1016/j.jcv.2020.104364.
[20] Guan W, Ni Z, Hu Yu, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708–20. https://doi.org/10.1056/NEJMoa2002032.
[21] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Articles Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.
[22] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
[23] Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020. https://doi.org/10.1002/jmv.25783.
[24] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507–13. https://doi.org/10.1016/S0140-6736(20)30211-7.
[25] Clancy CJ, Nguyen MH. Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect? Clin Infect Dis 2020. https://doi.org/10.1093/cid/ciaa524.